BIOSIMILARS
— A Podcast Series —

The New Era of Management in Gastroenterology and Rheumatology

The Practical Use of Biosimilars in Rheumatology APP Practice

Host:
Amanda Mixon, PA-C

Guest:
Daric Mueller, PA-C

Learning Objective	Podcast Discussion Summary
Interpret the ACR White Paper on Biosimilars in Rheumatology	The American College of Rheumatology white paper on biosimilars is a review of the scientific evidence on the safety and efficacy of biosimilars published in 2017 and updated in 2020. The white paper concludes that biosimilars are safe and effective alternatives to reference products. It also states that biosimilars can be used in place of reference products, without any need to change the dose or frequency of administration. The white paper also discusses the potential benefits of using biosimilars, including cost, increased access, and improved patient outcomes.
Discuss the Use of Biosimilars in the Treatment of Rheumatic Disease	When transitioning patients in rheumatology from reference biologics to biosimilars, key considerations include ensuring therapeutic equivalence, as biosimilars must demonstrate similar safety and efficacy profiles to their reference products. It's important to consider patient education and communication, addressing any concerns or misconceptions about biosimilars to ensure adherence and confidence in the treatment. Additionally, monitoring for any adverse reactions or changes in clinical response during the transition is crucial to maintain the effectiveness of the therapy and patient well-being.
Produce Strategies for Implementing the Use of Biosimilars in Rheumatology Practice	Implementing the use of biosimilars in rheumatology practice requires a multifaceted strategy. Firstly, it's essential to educate healthcare professionals about the efficacy, safety, and regulatory aspects of biosimilars to ensure informed prescribing decisions. Secondly, developing patient education materials and communication plans is crucial to address any concerns and misconceptions, thereby enhancing patient acceptance and adherence. Finally, establishing a robust monitoring system to track patient outcomes and potential adverse effects post-transition can ensure the safe and effective use of biosimilars in clinical practice.

Supported by educational grants from Amgen and Pfizer, Inc.